制藥企業(yè)應收賬款創(chuàng)新管理研究

制藥企業(yè)應收賬款創(chuàng)新管理研究一、本文概述Overviewofthisarticle隨著全球經(jīng)濟的持續(xù)發(fā)展和市場競爭的日益激烈，制藥企業(yè)面臨著越來越大的運營壓力。應收賬款作為制藥企業(yè)流動資金的重要組成部分，其管理效率直接影響到企業(yè)的資金周轉(zhuǎn)和運營效率。因此，創(chuàng)新應收賬款管理策略，提高應收賬款的回收效率，對于制藥企業(yè)而言具有重大的現(xiàn)實意義。Withthecontinuousdevelopmentoftheglobaleconomyandincreasinglyfiercemarketcompetition,pharmaceuticalcompaniesarefacingincreasingoperationalpressure.Asanimportantcomponentoftheworkingcapitalofpharmaceuticalenterprises,accountsreceivablemanagementefficiencydirectlyaffectstheturnoverandoperationalefficiencyoftheenterprise.Therefore,innovatingaccountsreceivablemanagementstrategiesandimprovingtheefficiencyofaccountsreceivablecollectionhavesignificantpracticalsignificanceforpharmaceuticalcompanies.本文旨在深入探討制藥企業(yè)應收賬款的創(chuàng)新管理策略，分析當前應收賬款管理存在的問題及其成因，并提出相應的改進措施。文章首先將對制藥企業(yè)的應收賬款管理現(xiàn)狀進行梳理，揭示當前應收賬款管理面臨的挑戰(zhàn)和困難。然后，通過案例分析和理論探討，深入剖析應收賬款管理創(chuàng)新的理論基礎(chǔ)和實踐路徑。在此基礎(chǔ)上，本文將提出一系列針對制藥企業(yè)應收賬款管理的創(chuàng)新策略，包括優(yōu)化客戶信用管理、強化風險控制、提升信息化水平、完善內(nèi)部管理制度等。Thisarticleaimstoexploreinnovativemanagementstrategiesforaccountsreceivableinpharmaceuticalcompanies,analyzetheproblemsandcausesofcurrentaccountsreceivablemanagement,andproposecorrespondingimprovementmeasures.Thearticlewillfirstsortoutthecurrentsituationofaccountsreceivablemanagementinpharmaceuticalcompanies,revealingthechallengesanddifficultiesfacedbycurrentaccountsreceivablemanagement.Then,throughcaseanalysisandtheoreticalexploration,wewilldelveintothetheoreticalfoundationandpracticalpathofinnovativeaccountsreceivablemanagement.Onthisbasis,thisarticlewillproposeaseriesofinnovativestrategiesforpharmaceuticalenterpriseaccountsreceivablemanagement,includingoptimizingcustomercreditmanagement,strengtheningriskcontrol,improvinginformationtechnologylevel,andimprovinginternalmanagementsystems.本文的研究不僅有助于豐富和完善制藥企業(yè)應收賬款管理的理論體系，而且可以為制藥企業(yè)提供具有可操作性的管理實踐指導。通過實施這些創(chuàng)新管理策略，制藥企業(yè)可以進一步提高應收賬款的回收效率，降低資金成本，增強企業(yè)的競爭力和可持續(xù)發(fā)展能力。Theresearchinthisarticlenotonlyhelpstoenrichandimprovethetheoreticalsystemofaccountsreceivablemanagementinpharmaceuticalenterprises,butalsoprovidespracticalmanagementguidancewithoperabilityforpharmaceuticalenterprises.Byimplementingtheseinnovativemanagementstrategies,pharmaceuticalcompaniescanfurtherimprovetheefficiencyofaccountsreceivablecollection,reducecapitalcosts,enhancetheircompetitivenessandsustainabledevelopmentcapabilities.二、制藥企業(yè)應收賬款現(xiàn)狀分析AnalysisoftheCurrentSituationofAccountsReceivableinPharmaceuticalEnterprises在當前的市場環(huán)境下，制藥企業(yè)的應收賬款管理面臨著諸多挑戰(zhàn)。應收賬款作為企業(yè)流動資金的重要組成部分，其管理效率和風險控制能力直接關(guān)系到企業(yè)的運營效率和財務安全。然而，目前許多制藥企業(yè)在應收賬款管理方面存在一些問題，這些問題不僅影響了企業(yè)的資金周轉(zhuǎn)，還可能引發(fā)財務風險。Inthecurrentmarketenvironment,pharmaceuticalcompaniesfacemanychallengesinaccountsreceivablemanagement.Asanimportantcomponentofacompany'sworkingcapital,themanagementefficiencyandriskcontrolabilityofaccountsreceivablearedirectlyrelatedtotheoperationalefficiencyandfinancialsecurityofthecompany.However,manypharmaceuticalcompaniescurrentlyfacesomeissuesinaccountsreceivablemanagement,whichnotonlyaffecttheircashflowbutmayalsoleadtofinancialrisks.制藥企業(yè)應收賬款的規(guī)模較大。由于藥品銷售的特殊性，往往需要給予客戶一定的信用期限，導致應收賬款的積累。隨著市場競爭的加劇，一些企業(yè)為了擴大市場份額，過度放寬信用政策，進一步增加了應收賬款的規(guī)模。Thescaleofaccountsreceivableforpharmaceuticalcompaniesisrelativelylarge.Duetotheparticularityofdrugsales,itisoftennecessarytogivecustomersacertaincreditperiod,whichleadstotheaccumulationofaccountsreceivable.Withtheintensificationofmarketcompetition,someenterpriseshaveexcessivelyrelaxedcreditpoliciesinordertoexpandtheirmarketshare,furtherincreasingthescaleofaccountsreceivable.應收賬款的回收周期較長。藥品銷售涉及到多個環(huán)節(jié)，包括醫(yī)院、藥店、經(jīng)銷商等，這些環(huán)節(jié)之間的結(jié)算周期較長，導致應收賬款的回收周期也相應延長。一些客戶可能存在拖欠款項的情況，進一步增加了應收賬款的回收難度。Thecollectioncycleofaccountsreceivableisrelativelylong.Drugsalesinvolvemultiplelinks,includinghospitals,pharmacies,distributors,etc.,andthesettlementcyclebetweentheselinksisrelativelylong,resultinginacorrespondingextensionofthecollectioncycleofaccountsreceivable.Somecustomersmayhaveoutstandingpayments,furtherincreasingthedifficultyofcollectingaccountsreceivable.再次，應收賬款的風險控制不足。一些制藥企業(yè)在應收賬款管理方面缺乏完善的風險控制機制，無法對客戶的信用狀況進行有效評估和控制。這可能導致企業(yè)面臨壞賬風險，進而影響企業(yè)的財務穩(wěn)健性。Onceagain,theriskcontrolofaccountsreceivableisinsufficient.Somepharmaceuticalcompanieslackasoundriskcontrolmechanisminaccountsreceivablemanagement,makingitdifficulttoeffectivelyevaluateandcontrolthecreditstatusofcustomers.Thismayleadtotheriskofbaddebtsforenterprises,whichinturnaffectstheirfinancialstability.應收賬款的信息化管理水平有待提高。隨著信息技術(shù)的發(fā)展，應收賬款管理也應逐步實現(xiàn)信息化、智能化。然而，目前一些制藥企業(yè)在應收賬款管理方面的信息化水平較低，無法有效利用信息技術(shù)提高管理效率和風險控制能力。Thelevelofinformationmanagementofaccountsreceivableneedstobeimproved.Withthedevelopmentofinformationtechnology,accountsreceivablemanagementshouldgraduallyachieveinformatizationandintelligence.However,currentlysomepharmaceuticalcompanieshavearelativelylowlevelofinformatizationinaccountsreceivablemanagement,andareunabletoeffectivelyutilizeinformationtechnologytoimprovemanagementefficiencyandriskcontrolcapabilities.當前制藥企業(yè)在應收賬款管理方面面臨著諸多挑戰(zhàn)和問題。為了解決這些問題，企業(yè)需要加強應收賬款的風險控制、優(yōu)化信用政策、提高信息化管理水平等措施，以實現(xiàn)應收賬款的高效管理和風險控制。Currently,pharmaceuticalcompaniesfacemanychallengesandproblemsinaccountsreceivablemanagement.Inordertosolvetheseproblems,enterprisesneedtostrengthenriskcontrolofaccountsreceivable,optimizecreditpolicies,improveinformationmanagementlevel,andothermeasurestoachieveefficientmanagementandriskcontrolofaccountsreceivable.三、創(chuàng)新管理理論及其在應收賬款管理中的應用InnovativeManagementTheoryandItsApplicationinAccountsReceivableManagement在制藥企業(yè)應收賬款的管理中，創(chuàng)新管理理論的應用顯得尤為重要。傳統(tǒng)的應收賬款管理方式往往側(cè)重于風險控制和賬款回收，但在現(xiàn)代商業(yè)環(huán)境中，這種單一的管理方式已無法滿足企業(yè)快速發(fā)展的需求。因此，引入創(chuàng)新管理理論，可以為制藥企業(yè)的應收賬款管理帶來新的思路和方法。Theapplicationofinnovativemanagementtheoryisparticularlyimportantinthemanagementofaccountsreceivableinpharmaceuticalcompanies.Traditionalaccountsreceivablemanagementmethodsoftenfocusonriskcontrolandaccountrecovery,butinmodernbusinessenvironments,thissinglemanagementmethodcannolongermeettheneedsofrapiddevelopmentofenterprises.Therefore,introducinginnovativemanagementtheorycanbringnewideasandmethodstotheaccountsreceivablemanagementofpharmaceuticalenterprises.創(chuàng)新管理理論主張在管理中注重創(chuàng)新、靈活性和適應性。在應收賬款管理中，這意味著企業(yè)需要根據(jù)市場環(huán)境、客戶需求和自身經(jīng)營狀況，不斷調(diào)整和優(yōu)化管理策略。例如，企業(yè)可以通過建立客戶信用評估體系，對客戶進行分類管理，以便更好地控制風險和提高賬款回收效率。同時，企業(yè)還可以利用大數(shù)據(jù)、人工智能等先進技術(shù)，對賬款數(shù)據(jù)進行深度分析，發(fā)現(xiàn)潛在風險和問題，并采取相應的應對措施。Thetheoryofinnovativemanagementadvocatesemphasizinginnovation,flexibility,andadaptabilityinmanagement.Inaccountsreceivablemanagement,thismeansthatenterprisesneedtocontinuouslyadjustandoptimizemanagementstrategiesbasedonmarketenvironment,customerneeds,andtheirownoperatingconditions.Forexample,enterprisescanestablishacustomercreditevaluationsystemtoclassifyandmanagecustomers,inordertobettercontrolrisksandimprovetheefficiencyofaccountrecovery.Atthesametime,enterprisescanalsoutilizeadvancedtechnologiessuchasbigdataandartificialintelligencetoconductin-depthanalysisofaccountreconciliationdata,identifypotentialrisksandproblems,andtakecorrespondingresponsemeasures.創(chuàng)新管理理論還強調(diào)團隊合作和知識共享。在應收賬款管理中，這意味著企業(yè)需要建立一個跨部門、跨層級的協(xié)作機制，讓各部門之間能夠共享信息、資源和經(jīng)驗。這不僅可以提高管理效率和質(zhì)量，還可以促進企業(yè)內(nèi)部的知識創(chuàng)新和經(jīng)驗積累。Innovativemanagementtheoryalsoemphasizesteamworkandknowledgesharing.Inaccountsreceivablemanagement,thismeansthatenterprisesneedtoestablishacrossdepartmentalandcrosslevelcollaborationmechanism,allowingdepartmentstoshareinformation,resources,andexperience.Thiscannotonlyimprovemanagementefficiencyandquality,butalsopromoteknowledgeinnovationandexperienceaccumulationwithintheenterprise.創(chuàng)新管理理論在制藥企業(yè)應收賬款管理中的應用具有重要意義。通過引入創(chuàng)新管理理論和方法，企業(yè)可以更好地應對市場變化、提高管理效率和質(zhì)量、降低風險和成本，從而實現(xiàn)可持續(xù)發(fā)展。Theapplicationofinnovativemanagementtheoryinaccountsreceivablemanagementofpharmaceuticalenterprisesisofgreatsignificance.Byintroducinginnovativemanagementtheoriesandmethods,enterprisescanbetterrespondtomarketchanges,improvemanagementefficiencyandquality,reducerisksandcosts,andthusachievesustainabledevelopment.四、制藥企業(yè)應收賬款創(chuàng)新管理策略與實踐InnovativeManagementStrategiesandPracticesforAccountsReceivableinPharmaceuticalEnterprises應收賬款管理在制藥企業(yè)中具有極其重要的地位，其不僅關(guān)乎企業(yè)的現(xiàn)金流狀況，更是影響企業(yè)運營效率和市場競爭力的關(guān)鍵因素。因此，實施創(chuàng)新的應收賬款管理策略與實踐，對于制藥企業(yè)而言，具有迫切性和重要性。Accountsreceivablemanagementplaysanextremelyimportantroleinpharmaceuticalenterprises,asitnotonlyaffectsthecashflowstatusoftheenterprise,butalsoisakeyfactoraffectingtheoperationalefficiencyandmarketcompetitivenessoftheenterprise.Therefore,implementinginnovativeaccountsreceivablemanagementstrategiesandpracticesisurgentandimportantforpharmaceuticalcompanies.（1）風險評估與分類管理：制藥企業(yè)應對客戶進行全面的信用風險評估，根據(jù)評估結(jié)果將客戶分為不同的信用等級，實施差異化的收款政策和信用額度。對于信用等級較低的客戶，應適當提高預付款比例或采取其他風險緩釋措施。(1)Riskassessmentandclassificationmanagement:Pharmaceuticalcompaniesshouldconductacomprehensivecreditriskassessmentoftheircustomers,classifythemintodifferentcreditlevelsbasedontheassessmentresults,andimplementdifferentiatedpaymentpoliciesandcreditlimits.Forcustomerswithlowercreditratings,theprepaymentratioshouldbeappropriatelyincreasedorotherriskmitigationmeasuresshouldbetaken.（2）動態(tài)監(jiān)控與預警機制：建立應收賬款的動態(tài)監(jiān)控體系，定期對賬齡、逾期賬款進行統(tǒng)計和分析，及時發(fā)現(xiàn)潛在風險。同時，設(shè)立預警機制，當賬齡超過一定期限或逾期賬款達到一定比例時，及時啟動風險應對措施。(2)Dynamicmonitoringandearlywarningmechanism:Establishadynamicmonitoringsystemforaccountsreceivable,regularlycollectandanalyzeagingandoverdueaccounts,andpromptlyidentifypotentialrisks.Atthesametime,establishawarningmechanismtopromptlyinitiateriskresponsemeasureswhentheaccountageexceedsacertainperiodortheoverdueaccountsreachacertainproportion.（3）優(yōu)化合同管理與履約監(jiān)督：在簽訂銷售合同時，應明確收款條款、違約責任和糾紛解決機制，減少因合同條款不清而產(chǎn)生的收款糾紛。同時，加強履約監(jiān)督，確?？蛻舭磿r付款。(3)Optimizecontractmanagementandperformancesupervision:Whensigningsalescontracts,paymentterms,breachofcontractresponsibilities,anddisputeresolutionmechanismsshouldbeclearlydefinedtoreducepaymentdisputescausedbyunclearcontractterms.Atthesametime,strengthenperformancesupervisiontoensurethatcustomersmaketimelypayments.（1）引入金融科技手段：借助大數(shù)據(jù)、人工智能等金融科技手段，對客戶的經(jīng)營狀況、信用記錄等進行深度挖掘和分析，提高信用風險評估的準確性和效率。(1)Introducingfinancialtechnologytools:Byutilizingfinancialtechnologytoolssuchasbigdataandartificialintelligence,wecandeeplyexploreandanalyzethebusinessstatusandcreditrecordsofcustomers,therebyimprovingtheaccuracyandefficiencyofcreditriskassessment.（2）建立跨部門協(xié)同機制：應收賬款管理不僅是財務部門的職責，還需要銷售、市場、法務等多個部門的協(xié)同配合。因此，制藥企業(yè)應建立跨部門的協(xié)同機制，形成合力推動應收賬款管理工作的深入開展。(2)Establishingacrossdepartmentalcollaborationmechanism:Accountsreceivablemanagementisnotonlytheresponsibilityofthefinancedepartment,butalsorequiresthecollaborationandcooperationofmultipledepartmentssuchassales,marketing,andlegal.Therefore,pharmaceuticalcompaniesshouldestablishacrossdepartmentalcollaborativemechanismtoformajointforcetopromotethein-depthdevelopmentofaccountsreceivablemanagement.（3）加強員工培訓與意識提升：定期對員工進行應收賬款管理相關(guān)知識的培訓和教育，提高員工的風險意識和責任意識，確保各項管理策略能夠得到有效執(zhí)行。(3)Strengthenemployeetrainingandawarenessenhancement:Regularlyprovidetrainingandeducationonaccountsreceivablemanagementrelatedknowledgetoemployees,enhancetheirriskandresponsibilityawareness,andensurethatvariousmanagementstrategiescanbeeffectivelyimplemented.通過實施創(chuàng)新的應收賬款管理策略與實踐，制藥企業(yè)可以更好地應對市場變化和客戶風險，提高應收賬款回收效率和質(zhì)量，為企業(yè)的健康發(fā)展提供有力保障。Byimplementinginnovativeaccountsreceivablemanagementstrategiesandpractices,pharmaceuticalcompaniescanbetterrespondtomarketchangesandcustomerrisks,improvetheefficiencyandqualityofaccountsreceivablecollection,andprovidestrongguaranteesforthehealthydevelopmentoftheenterprise.五、制藥企業(yè)應收賬款創(chuàng)新管理效果評估與優(yōu)化EvaluationandOptimizationofInnovativeManagementEffectivenessforAccountsReceivableinPharmaceuticalEnterprises應收賬款管理作為制藥企業(yè)財務管理的重要環(huán)節(jié)，其實施效果的評估與優(yōu)化至關(guān)重要。通過有效的評估，企業(yè)能夠了解當前應收賬款管理策略的優(yōu)點與不足，從而為后續(xù)的優(yōu)化工作提供明確的方向。Accountsreceivablemanagement,asanimportantpartoffinancialmanagementinpharmaceuticalenterprises,iscrucialforevaluatingandoptimizingitsimplementationeffectiveness.Througheffectiveevaluation,enterprisescanunderstandtheadvantagesanddisadvantagesofthecurrentaccountsreceivablemanagementstrategy,therebyprovidingcleardirectionforsubsequentoptimizationwork.應收賬款管理效果的評估應基于多個維度進行，包括但不限于：應收賬款周轉(zhuǎn)率、壞賬率、賬齡結(jié)構(gòu)、客戶信用管理效果等。這些指標能夠全面反映制藥企業(yè)在應收賬款管理方面的效率和風險控制能力。Theevaluationoftheeffectivenessofaccountsreceivablemanagementshouldbebasedonmultipledimensions,includingbutnotlimitedto:accountsreceivableturnoverrate,baddebtrate,agingstructure,customercreditmanagementeffectiveness,etc.Theseindicatorscancomprehensivelyreflecttheefficiencyandriskcontrolabilityofpharmaceuticalcompaniesinaccountsreceivablemanagement.應收賬款周轉(zhuǎn)率能夠反映企業(yè)應收賬款的流動性，周轉(zhuǎn)率越高，說明企業(yè)資金回籠速度越快，資金使用效率越高。壞賬率體現(xiàn)了企業(yè)應收賬款的風險水平，壞賬率越低，說明企業(yè)應收賬款質(zhì)量越好。賬齡結(jié)構(gòu)分析能夠揭示不同賬齡應收賬款的分布情況，為企業(yè)制定針對性的收款策略提供依據(jù)?？蛻粜庞霉芾硇Чu估能夠反映企業(yè)在客戶信用管理方面的能力和水平，為企業(yè)后續(xù)的客戶選擇和信用政策制定提供參考。Theaccountsreceivableturnoverratecanreflecttheliquidityofacompany'saccountsreceivable.Thehighertheturnoverrate,thefasterthecompany'sfundsarewithdrawnandthehighertheefficiencyoffundutilization.Thebaddebtratereflectstherisklevelofacompany'saccountsreceivable,andthelowerthebaddebtrate,thebetterthequalityofthecompany'saccountsreceivable.Agingstructureanalysiscanrevealthedistributionofaccountsreceivablewithdifferentages,providingabasisforenterprisestoformulatetargetedcollectionstrategies.Theevaluationofcustomercreditmanagementeffectivenesscanreflecttheabilityandlevelofenterprisesincustomercreditmanagement,providingreferenceforsubsequentcustomerselectionandcreditpolicyformulation.基于應收賬款管理效果的評估結(jié)果，企業(yè)可以制定針對性的優(yōu)化策略。具體而言，可以從以下幾個方面進行：Basedontheevaluationresultsofaccountsreceivablemanagementeffectiveness,enterprisescandeveloptargetedoptimizationstrategies.Specifically,itcanbeapproachedfromthefollowingaspects:完善客戶信用管理體系：通過建立完善的客戶信用管理體系，對企業(yè)客戶進行科學分類和信用評估，為不同信用等級的客戶制定不同的信用政策和收款策略。同時，加強客戶信用信息的收集和更新，確保信用評估的準確性和時效性。Improvecustomercreditmanagementsystem:Byestablishingacomprehensivecustomercreditmanagementsystem,scientificallyclassifyandevaluatecorporatecustomers,anddevelopdifferentcreditpoliciesandpaymentstrategiesforcustomerswithdifferentcreditlevels.Atthesametime,strengthenthecollectionandupdatingofcustomercreditinformationtoensuretheaccuracyandtimelinessofcreditevaluation.強化應收賬款日常監(jiān)控與催收：建立健全的應收賬款日常監(jiān)控機制，定期對賬齡結(jié)構(gòu)、壞賬率等關(guān)鍵指標進行分析和預警。同時，加強應收賬款催收工作，針對不同賬齡和信用等級的客戶制定不同的催收策略，提高應收賬款回收率和效率。Strengthendailymonitoringandcollectionofaccountsreceivable:Establishasoundmechanismfordailymonitoringofaccountsreceivable,andregularlyanalyzeandwarnkeyindicatorssuchasagingstructureandbaddebtrate.Atthesametime,strengthenthecollectionofaccountsreceivable,developdifferentcollectionstrategiesforcustomerswithdifferentagesandcreditlevels,andimprovethecollectionrateandefficiencyofaccountsreceivable.優(yōu)化收款流程與風險控制：通過優(yōu)化收款流程，減少收款環(huán)節(jié)和時間，提高收款效率。同時，加強風險控制，對應收賬款進行風險分類和評估，及時采取風險應對措施，降低壞賬損失和風險水平。Optimizingthecollectionprocessandriskcontrol:Byoptimizingthecollectionprocess,reducingthecollectionprocessandtime,andimprovingcollectionefficiency.Atthesametime,strengthenriskcontrol,classifyandevaluateaccountsreceivablerisks,taketimelyriskresponsemeasures,andreducebaddebtlossesandrisklevels.提升財務管理水平：加強財務管理人員的培訓和能力提升，提高財務管理水平。通過引入先進的財務管理理念和技術(shù)手段，提高應收賬款管理的專業(yè)化和智能化水平。Improvefinancialmanagementlevel:Strengthenthetrainingandabilityenhancementoffinancialmanagementpersonnel,andimprovetheleveloffinancialmanagement.Byintroducingadvancedfinancialmanagementconceptsandtechnicalmeans,weaimtoimprovetheprofessionalismandintelligencelevelofaccountsreceivablemanagement.制藥企業(yè)應收賬款創(chuàng)新管理效果的評估與優(yōu)化是一個持續(xù)的過程。企業(yè)需要不斷完善客戶信用管理體系、強化應收賬款日常監(jiān)控與催收、優(yōu)化收款流程與風險控制以及提升財務管理水平等方面的工作，以實現(xiàn)應收賬款管理的持續(xù)優(yōu)化和提升。Theevaluationandoptimizationoftheeffectivenessofinnovativemanagementofaccountsreceivableinpharmaceuticalenterprisesisacontinuousprocess.Enterprisesneedtocontinuouslyimprovetheircustomercreditmanagementsystem,strengthendailymonitoringandcollectionofaccountsreceivable,optimizethecollectionprocessandriskcontrol,andenhancetheirfinancialmanagementlevelinordertoachievecontinuousoptimizationandenhancementofaccountsreceivablemanagement.六、結(jié)論與展望ConclusionandOutlook本文通過對制藥企業(yè)應收賬款創(chuàng)新管理的研究，深入探討了當前制藥企業(yè)在應收賬款管理上面臨的問題及其成因，并針對性地提出了創(chuàng)新管理策略。研究認為，應收賬款管理對于制藥企業(yè)的資金流動、風險控制以及可持續(xù)發(fā)展具有重要意義。創(chuàng)新管理策略的實施，如引入金融科技手段、建立全面的信用管理體系、優(yōu)化內(nèi)部流程等，可以有效提高應收賬款的回收效率，降低壞賬風險，進而增強企業(yè)的市場競爭力。Thisarticleconductsresearchoninnovativemanagementofaccountsreceivableinpharmaceuticalenterprises,anddeeplyexplorestheproblemsandcausesfacedbypharmaceuticalenterprisesinaccountsreceivablemanagement,andproposestargetedinnovativemanagementstrategies.Researchsuggeststhataccountsreceivablemanagementisofgreatsignificancefor